TrialBlood2026
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
Lihua E Budde et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
TrialBlood2026
Lihua E Budde et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.